Catalyst Pharmaceuticals(CPRX)
Focus: Catalyst is a publicly traded specialty pharma company focused on small molecules for neurology and addiction treatment, generating nearly $400M in revenue with a highly concentrated portfolio anchored on FIRDAPSE.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
2-1 this month
Stable — net -1 jobs in 30d
3 added, 4 removed. Backfill posture.
Should You Work at Catalyst Pharmaceuticals?
AI assessmentCatalyst offers stable income and exposure to specialty neurology markets, but post-acquisition uncertainty and single-product dependency make it a cautious choice for long-term career growth.
Why Work Here
- Strong financial foundation with $518M cash and $71M net income in FY2025, providing stability and investment capacity.
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$398M
Key Products
$146M Part DStable
Peak10.3yr
Franchise cornerstone driving 67% of company revenue; broad-spectrum potassium channel blocker with extended exclusivity until 2037.
Help build intelligence for Catalyst Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.